Category: Vaccine Safety

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel

Posted on | Posted on John Murphy | Leave a Comment on Protection by a Fourth Dose of BNT162b2 against Omicron in Israel

Authors: Yinon M. Bar-On, M.Sc., Yair Goldberg, Ph.D., Micha Mandel, Ph.D., Omri Bodenheimer, M.Sc., Ofra Amir, Ph.D., Laurence Freedman, Ph.D., Sharon Alroy-Preis, M.D., Nachman Ash, M.D., Amit Huppert, Ph.D., and Ron Milo, Ph.D. April 5, 2022 DOI: 10.1056/NEJMoa2201570 NEW ENGLAND JOURNAL OF MEDICINE Abstract BACKGROUND On January 2, 2022, Israel began administering a fourth dose of BNT162b2 vaccine to persons 60 years of age […]

Spike protein in mRNA COVID vaccines: One of the most bioactive substances known to mankind

Posted on | Posted on John Murphy | Leave a Comment on Spike protein in mRNA COVID vaccines: One of the most bioactive substances known to mankind

Source: https://www.planet-today.com/2022/03/spike-protein-in-mrna-covid-vaccines.html The spike protein present in Wuhan coronavirus (COVID-19) vaccines is one of the most bioactive and potentially damaging substances known to mankind. It penetrates the blood-brain barrier, cell nucleus and even affects DNA replication. The spike protein appears to reprogram the immune system in a strange way. The BNT162b2 mRNA vaccine against the COVID-19 […]

Bone Marrow Suppression Secondary to the COVID-19 Booster Vaccine: A Case Report

Posted on | Posted on John Murphy | Leave a Comment on Bone Marrow Suppression Secondary to the COVID-19 Booster Vaccine: A Case Report

Authors: Toral Shastri 1, Navkiran Randhawa 2, Ragia Aly 3, Masood Ghouse 3 PMID: 35210894 PMCID: PMC8863340DOI: 10.2147/JBM.S350290 Abstract As of September 2021, SARS-CoV-2 booster shots became widely available in the US to ensure continued protection against the virus. A temporal relationship has been previously reported between the first or second dose of the COVID-19 vaccine and the development of thrombocytopenia. However, adverse events related […]

SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis

Posted on | Posted on John Murphy | Leave a Comment on SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis

Authors: RALPH TURCHIANO   SEPTEMBER 8, 2021 •  Abstract Establishing the rate of post-vaccination cardiac myocarditis in the 12-15 and 16-17-year-old population in the context of their COVID-19 hospitalization risk is critical for developing a vaccination recommendation framework that balances harms with benefits for this patient demographic. Design, Setting and Participants: Using the Vaccine Adverse Event Reporting […]

Pfizer’s COVID-19 Vaccine Goes Into Liver Cells And Is Converted To DNA: Study

Posted on | Posted on John Murphy | Leave a Comment on Pfizer’s COVID-19 Vaccine Goes Into Liver Cells And Is Converted To DNA: Study

Authors Meiling Lee THURSDAY, MAR 03, 2022 – 07:40 PM The messenger RNA (mRNA) from Pfizer’s COVID-19 vaccine is able to enter human liver cells and is converted into DNA, according to Swedish researchers at Lund University. The researchers found that when the mRNA vaccine enters the human liver cells, it triggers the cell’s DNA, […]

Age- and Sex-Specific Incidence of Cerebral Venous Sinus Thrombosis Associated With Ad26.COV2.S COVID-19 Vaccination

Posted on | Posted on John Murphy | Leave a Comment on Age- and Sex-Specific Incidence of Cerebral Venous Sinus Thrombosis Associated With Ad26.COV2.S COVID-19 Vaccination

Authors: Aneel A. Ashrani, MD, MS1; Daniel J. Crusan, BS2; Tanya Petterson, MS2; et al JAMA Intern Med. 2022;182(1):80-83. doi:10.1001/jamainternmed.2021.6352 Recent reports1–4 suggest a possible association between Ad26.COV2.S (Johnson & Johnson/Janssen) COVID-19 vaccination and cerebral venous sinus thrombosis (CVST). Estimates of postvaccination CVST risk require accurate age- and sex-specific prepandemic CVST incidence rates; however, reported rates vary widely.5 We compared the age- and sex-specific CVST rates after […]

Myocarditis following mRNA vaccination against SARS-CoV-2, a case series

Posted on | Posted on John Murphy | Leave a Comment on Myocarditis following mRNA vaccination against SARS-CoV-2, a case series

Authors:William W.KingaMatthew R.PetersenaRalph M.MatarbJeffery B.BudwegaLydaCuervo PardocJohn W.Petersenb American Heart Journal Plus: Cardiology Research and Practice Volume 8, August 2021, 100042 Abstract Introduction mRNA COVID-19 vaccines have emerged as a new form of vaccination that has proven to be highly safe and effective against COVID-19 vaccination. Rare adverse events including myocarditis have been reported in the literature. […]